Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Merck | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Merck

Keytruda sales top $1.0 billion, up 194% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Merck
3Q Revenues: $10.3 billion (-2%)
3Q Loss: $56.0 million (earnings were $2.2 billion 3Q16)
YTD Revenues: $29.7 billion (flat)  
YTD Earnings: $3.5 billion (-24%)   
Comments: Pharmaceutical sales were down 3% to $9.2 billion in the quarter. Keytruda achieved sales of $1.0 billion, up 194% with new indications launched globally. Januvia sales were down 2% to $1.5 billion primarily due to pricing pressure partially offset by volume growth globally. Gardasil sales were down 22% to $675 million. PROQUAD, M-M-R II and VARIVAX sales were $519 million, up 4%. Zepatier sales were up 185% to $468 million. ZETIA / VYTORIN sales were down 51% to $462 million due to the loss of U.S. market exclusivity. ISENTRESS / ISENTRESS HD sales were down 17% to $310 million. ZOSTAVAX sales were up 23% to $234 million. Revenues in the quarter were reduced by approximately $240 million due to a borrowing from the U.S. CDC and Prevention Pediatric Vaccine Stockpile of GARDASIL 9, driven in part by the temporary production shutdown resulting from the cyber-attack, which unfavorably impacted revenues by approximately $135 million from lost sales in certain markets. Loss in the quarter reflects a $2.4 billion charge related to the formation of a strategic oncology collaboration with AstraZeneca.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters